Close
To find more information on UCLH Early Phase Cancer Clinical Trials, including eligibility criteria, click the hyperlinked Local Project Reference (LRP) ID, which will take you to the UCLH Find a Study database.
Additional early phase clinical trials recruiting Lung cohorts may be found in the Advanced Solid Tumour Trials Portfolio page.
APL-101-01Safety and efficacy of APL-101 in NSCLC and advanced solid tumors: Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors | |
|---|---|
| Local Project Reference: | 129619 |
| Principal Investigator: | Dr. Martin Forster |
| Drug Class/ Treatment: | APL-101 (C-Met Inhibitor) |
| Patient Population: | Non-Small Cell Lung Cancer (NSCLC) |
| Trial Hosted By - UCLH Clinical Research Facility (CRF) | |
ATX-NS-001 (CHIRON)ATX-NS-001 - ATL001 for the Treatment of Non-Small Cell Lung Cancer: An open label, multi-centre, phase I/IIa study evaluating the safety and clinical activity of neo-antigen reactive T cells in patients with advanced non-small cell lung cancer (CHIRON) | |
|---|---|
| Local Project Reference: | 18/0540 |
| Principal Investigator: | Dr. Martin Forster |
| Drug Class/ Treatment: | ATL001 - Autologous Clonal Neoantigen Reactive T-Cell (cNeT) |
| Patient Population: | Non-Small Cell Lung Cancer (NSCLC) |
| Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU) | |
CONCORDEA platform study of DNA damage response inhibitors in combination with conventional radiotherapy in non small cell lung cancer | |
|---|---|
| Local Project Reference: | 118073 |
| Principal Investigator: | Dr. Crispin Hiley |
| Drug Class/ Treatment: | Radiotherapy + Olaparib (PARP Inhibitor) or AZD1390 (Oral ATM Inhibitor) |
| Patient Population: | Non-Small Cell Lung Cancer |
| Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU) | |
DARWIN IIDARWIN2: Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity A phase II, multi-centre, non-randomised, molecularly stratified trial for NSCLC patients to study tumour heterogeneity using genomic analysis | |
|---|---|
| Local Project Reference: | 14/0274 |
| Principal Investigator: | Dr. Tanya Ahmad |
| Drug Class/ Treatment: |
|
| Patient Population: | Non-Small Cell Lung Cancer Only patients registered in the TRACERx study or patient with two fresh frozen primary tumour samples available, whose NSCLC have relapsed will be eligible for DARWIN2. |
| Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU) | |
